Literature DB >> 8172380

Pentoxifylline for intermittent claudication. A critical review.

E Ernst1.   

Abstract

Pentoxifylline was first introduced in Germany twenty years ago. Today it is the best researched oral drug for intermittent claudication. A total of seventeen placebo-controlled trials could be retrieved from the world literature. The majority of these studies show that pentoxifylline will prolong the walking distance in a statistically significant way. Even though these trials are conducted with considerable scientific rigor, important flaws can be identified. Whether the symptomatic improvement is clinically relevant is difficult to say and may depend on the patient's individual situation. These collective data show that pentoxifylline prolongs the walking distance in patients with intermittent claudication.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172380     DOI: 10.1177/000331979404500502

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  15 in total

1.  Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.

Authors:  S C Hood; D Moher; G G Barber
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

2.  Pentoxifylline reduces chronic post-ischaemia pain by alleviating microvascular dysfunction.

Authors:  J Vaigunda Ragavendran; A Laferrière; M Khorashadi; T J Coderre
Journal:  Eur J Pain       Date:  2013-07-31       Impact factor: 3.931

3.  Pharmacological management of intermittent claudication: a meta-analysis of randomised trials.

Authors:  D Moher; B Pham; M Ausejo; A Saenz; S Hood; G G Barber
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

4.  Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard.

Authors:  B Poon; J B Jowett; S A Stewart; R W Armstrong; G M Rishton; I S Chen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Process of care and outcomes in patients with peripheral arterial disease.

Authors:  Tracie C Collins; Rebecca J Beyth; David B Nelson; Nancy J Petersen; Maria E Suarez-Almazor; Ruth L Bush; Alan T Hirsch; Carol M Ashton
Journal:  J Gen Intern Med       Date:  2007-04-24       Impact factor: 5.128

6.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

Review 7.  Pentoxifylline for intermittent claudication.

Authors:  Kareem Salhiyyah; Rachel Forster; Eshan Senanayake; Mohammed Abdel-Hadi; Andrew Booth; Jonathan A Michaels
Journal:  Cochrane Database Syst Rev       Date:  2015-09-29

Review 8.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 9.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

10.  Pentoxifylline for intermittent claudication.

Authors:  Cathryn Broderick; Rachel Forster; Mohammed Abdel-Hadi; Kareem Salhiyyah
Journal:  Cochrane Database Syst Rev       Date:  2020-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.